Fezolinetant for Hot Flashes

Fezolinetant blocks the neurokinin 3 receptor, part of a signaling pathway involved in the brain's temperature-control center. It reduces vasomotor symptoms without supplying estrogen or progesterone.

Its approved purpose is specific: moderate to severe menopause vasomotor symptoms. It is not a treatment for every symptom attributed to menopause and does not replace local treatment for vaginal dryness or a bone-health plan. If several symptoms need care, discuss each treatment goal.

A nonhormonal option may be useful when someone prefers it or systemic HRT is unsuitable. That still requires assessment of the medicine's own contraindications and monitoring needs.

The label describes two randomized trials in postmenopausal women averaging at least seven moderate to severe vasomotor symptoms daily. The principal comparisons measured changes in symptom frequency and severity at weeks four and twelve.

The trials included substantial improvement in the placebo groups as well. The extra benefit over placebo is more informative than quoting only the decline from the treated group's starting score. Response should be assessed against your own baseline frequency, sleep disruption, and daily interference.

The current US label has a boxed warning for liver injury. Tests before starting include ALT, AST, alkaline phosphatase, and bilirubin. The label prohibits starting when ALT or AST is at least twice the laboratory's upper limit of normal or total bilirubin is at least twice that limit.

Follow-up liver tests are required monthly for the first three months, then at months six and nine. Abnormal results may require additional testing or stopping. A person can have abnormal enzymes without noticing symptoms, which is why feeling well does not replace the scheduled tests.

The label advises stopping the medicine immediately and seeking medical attention if new fatigue, appetite loss, nausea, vomiting, itching, yellow eyes or skin, pale stools, dark urine, or abdominal pain suggests liver injury. Do not wait for the next planned blood test.

FDA added the boxed warning in December 2024 after postmarketing liver injury. Before agreeing to treatment, confirm who orders each test, how results are communicated, and what happens if testing is delayed.

Veozah is contraindicated with known cirrhosis, severe kidney impairment or end-stage kidney disease, and medicines that inhibit CYP1A2. CYP1A2 is an enzyme involved in breaking down fezolinetant; inhibiting it can raise exposure.

The pharmacist or prescriber should check all medicines and supplements, including new prescriptions added after treatment begins. The contraindication includes weak, moderate, and strong CYP1A2 inhibitors. Do not stop another medicine on your own to make fezolinetant possible.

The US dose is one 45 mg tablet daily, with or without food. Report abdominal pain, diarrhea, insomnia, back pain, and other effects. Some overlap with liver-warning symptoms, so the care team needs the timing and severity.

Count hot flashes or sweat episodes for a brief baseline period and note their severity and nighttime disruption. At review, compare those details with treatment response, side effects, and the liver results.

Ask which alternatives are appropriate if benefit is inadequate or tests prevent continued use. A prescription decision should consider the burden of symptoms and the practical ability to complete monitoring, alongside other suitable hormonal or nonhormonal treatment.